Annuncio pubblicitario
Italia markets closed
  • FTSE MIB

    34.657,35
    +318,03 (+0,93%)
     
  • Dow Jones

    39.512,84
    +125,08 (+0,32%)
     
  • Nasdaq

    16.340,87
    -5,40 (-0,03%)
     
  • Nikkei 225

    38.229,11
    +155,13 (+0,41%)
     
  • Petrolio

    78,20
    -1,06 (-1,34%)
     
  • Bitcoin EUR

    56.511,78
    -1.908,62 (-3,27%)
     
  • CMC Crypto 200

    1.260,95
    -97,05 (-7,15%)
     
  • Oro

    2.366,90
    +26,60 (+1,14%)
     
  • EUR/USD

    1,0772
    -0,0012 (-0,11%)
     
  • S&P 500

    5.222,68
    +8,60 (+0,16%)
     
  • HANG SENG

    18.963,68
    +425,87 (+2,30%)
     
  • Euro Stoxx 50

    5.085,08
    +30,67 (+0,61%)
     
  • EUR/GBP

    0,8601
    -0,0007 (-0,08%)
     
  • EUR/CHF

    0,9760
    -0,0005 (-0,05%)
     
  • EUR/CAD

    1,4718
    -0,0026 (-0,17%)
     

Cara Therapeutics to Announce First Quarter 2023 Financial Results on May 15, 2023

Cara Therapeutics, Inc.
Cara Therapeutics, Inc.

STAMFORD, Conn., May 01, 2023 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA), a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced the Company will host a conference call and live audio webcast on Monday, May 15, 2023, at 4:30 p.m. ET to report first quarter 2023 financial results and provide a corporate update.

To participate in the conference call, please register here. Registrants will receive the dial-in numbers and a unique PIN.

A live audio webcast and archived replay of the call will be available under “Events & Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com.

ANNUNCIO PUBBLICITARIO

About Cara Therapeutics

Cara Therapeutics is a commercial-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus. The Company’s KORSUVA® (difelikefalin) injection is the first and only FDA-approved treatment for moderate-to-severe pruritus associated with chronic kidney disease in adults undergoing hemodialysis. The Company is developing an oral formulation of difelikefalin and has Phase 3 programs ongoing for the treatment of pruritus in patients with non-dialysis dependent advanced chronic kidney disease and atopic dermatitis. In addition, the Company has initiated a Phase 2/3 program of oral difelikefalin for the treatment of moderate-to-severe pruritus in patients with notalgia paresthetica. For more information, visit www.CaraTherapeutics.com and follow the company on Twitter, LinkedIn and Instagram.

MEDIA CONTACT:
Annie Spinetta
6 Degrees
973-768-2170
aspinetta@6degreespr.com

INVESTOR CONTACT:
Iris Francesconi, Ph.D.
Cara Therapeutics
203-406-3700
investor@caratherapeutics.com